Last 12 months
Inside the activity.
0 purchase rows · 36 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 30 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2017 Filed Feb 17, 2017 00:21 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
Exercise / conversionRestricted Stock Unit · Derivative | 737 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008019 · doc1.xml · derivative · entry 12 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,295 Underlying: Common Stock · 737 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. F9 · price: Not applicable. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:21 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
Exercise / conversionRestricted Stock Unit · Derivative | 472 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008019 · doc1.xml · derivative · entry 11 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,032 Underlying: Common Stock · 472 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split. F7 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:21 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
Exercise / conversionRestricted Stock Unit · Derivative | 403 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008019 · doc1.xml · derivative · entry 10 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,504 Underlying: Common Stock · 403 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. F9 · price: Not applicable. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:21 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
Exercise / conversionRestricted Stock Unit · Derivative | 545 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008019 · doc1.xml · derivative · entry 9 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,907 Underlying: Common Stock · 545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2014. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F9 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2014. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2014. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:21 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
GrantRestricted Stock Unit · Derivative | 2,295 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008019 · doc1.xml · derivative · entry 8 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,452 Underlying: Common Stock · 2,295 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. F9 · price: Not applicable. F4 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. F4 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:21 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 706 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0001140361-17-008019 · doc1.xml · derivative · entry 7 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 706 Underlying: Common Stock · 706 shares Expires 2027-02-13 F9 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2017. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:21 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 23,326 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0001140361-17-008019 · doc1.xml · derivative · entry 6 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,326 Underlying: Common Stock · 23,326 shares Expires 2027-02-13 F9 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2017. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:21 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
Tax withholdingCommon Stock | 719 | $141.60 | $101,810.40 |
DisclosureSEC source: 0001140361-17-008019 · doc1.xml · nonDerivative · entry 5 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,083 F2 · price: Closing price of Issuer's common stock on the NASDAQ market on February 14, 2017. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:21 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
Exercise / conversionCommon Stock | 737 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008019 · doc1.xml · nonDerivative · entry 4 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:21 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
Exercise / conversionCommon Stock | 472 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008019 · doc1.xml · nonDerivative · entry 3 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:21 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
Exercise / conversionCommon Stock | 403 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008019 · doc1.xml · nonDerivative · entry 2 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,593 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:21 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
Exercise / conversionCommon Stock | 545 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008019 · doc1.xml · nonDerivative · entry 1 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 52 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on December 31, 2016. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionRestricted Stock Unit · Derivative | 811 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008018 · doc1.xml · derivative · entry 10 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,515 Underlying: Common Stock · 811 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. F7 · price: Not applicable. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionRestricted Stock Unit · Derivative | 629 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008018 · doc1.xml · derivative · entry 9 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,326 Underlying: Common Stock · 629 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split. F7 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionRestricted Stock Unit · Derivative | 726 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008018 · doc1.xml · derivative · entry 8 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,955 Underlying: Common Stock · 726 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F7 · price: Not applicable. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
GrantRestricted Stock Unit · Derivative | 2,295 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008018 · doc1.xml · derivative · entry 7 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,681 Underlying: Common Stock · 2,295 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. F7 · price: Not applicable. F3 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. F3 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 706 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0001140361-17-008018 · doc1.xml · derivative · entry 6 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 706 Underlying: Common Stock · 706 shares Expires 2027-02-13 F7 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2018. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 23,326 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0001140361-17-008018 · doc1.xml · derivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,326 Underlying: Common Stock · 23,326 shares Expires 2027-02-13 F7 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2018. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Tax withholdingCommon Stock | 809 | $141.60 | $114,554.40 |
DisclosureSEC source: 0001140361-17-008018 · doc1.xml · nonDerivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,668 F1 · price: Closing price of Issuer's common stock on the NASDAQ market on February 14, 2017. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionCommon Stock | 811 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008018 · doc1.xml · nonDerivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionCommon Stock | 629 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008018 · doc1.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionCommon Stock | 726 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008018 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008017 · doc1.xml · derivative · entry 10 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,708 Underlying: Common Stock · 1,774 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. F6 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,160 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008017 · doc1.xml · derivative · entry 9 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,482 Underlying: Common Stock · 2,160 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2014 and has been adjusted to reflect the Stock Split. F6 · price: Not applicable. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2014 and has been adjusted to reflect the Stock Split. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2014 and has been adjusted to reflect the Stock Split. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008017 · doc1.xml · derivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,642 Underlying: Common Stock · 2,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. The RSUs vested in five equal annual installments, beginning February 14, 2013. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F6 · price: Not applicable. F3 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. The RSUs vested in five equal annual installments, beginning February 14, 2013. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F3 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. The RSUs vested in five equal annual installments, beginning February 14, 2013. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 706 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0001140361-17-008017 · doc1.xml · derivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 706 Underlying: Common Stock · 706 shares Expires 2027-02-13 F6 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2018. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 110,211 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0001140361-17-008017 · doc1.xml · derivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,211 Underlying: Common Stock · 110,211 shares Expires 2027-02-13 F6 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2018. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Tax withholdingCommon Stock | 3,159 | $141.60 | $447,314.40 |
DisclosureSEC source: 0001140361-17-008017 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 993,661 F1 · price: Closing price of Issuer's common stock on the NASDAQ market on February 14, 2017. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 1,774 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008017 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 996,820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 2,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008017 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 995,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 2,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008017 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 992,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 22:27 UTC |
END WILLIAM TDirector
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 6,602 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-17-007452 · doc1.xml · derivative · entry 2 END WILLIAM T · CIK 0001184157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,602 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 3,301 shares on February 14, 2012, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split").? The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 22:27 UTC |
END WILLIAM TDirector
|
Exercise / conversionCommon Stock | 6,602 | $38.80 | $256,124.59 |
DisclosureSEC source: 0001140361-17-007452 · doc1.xml · nonDerivative · entry 1 END WILLIAM T · CIK 0001184157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2017 Filed Feb 9, 2017 22:21 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 9,924 | Not disclosed Strike: $26.66 | Not disclosed |
DisclosureSEC source: 0001140361-17-005456 · doc1.xml · derivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,924 shares Expires 2017-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,962 shares on February 14, 2011, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split").? The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 08, 2017 Filed Feb 9, 2017 22:21 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 970 | $142.24 | $137,971.05 |
DisclosureSEC source: 0001140361-17-005456 · doc1.xml · nonDerivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,311 F1 · shares: Sale was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person. F3 · price: Represents the weighted average sales price of the shares sold ranging from a low of $141.06 to a high of $142.83 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 08, 2017 Filed Feb 9, 2017 22:21 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 8,954 | $141.57 | $1,267,619.57 |
DisclosureSEC source: 0001140361-17-005456 · doc1.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,281 F1 · shares: Sale was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person. F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $141.02 to a high of $142.02 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 08, 2017 Filed Feb 9, 2017 22:21 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionCommon Stock | 9,924 | $26.66 | $264,524.22 |
DisclosureSEC source: 0001140361-17-005456 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2017 Filed Feb 9, 2017 22:21 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 36,250 | Not disclosed Strike: $26.66 | Not disclosed |
DisclosureSEC source: 0001140361-17-005455 · doc1.xml · derivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,250 shares Expires 2017-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: Grant of option to buy 78,125 shares of IDEXX Laboratories, Inc. common stock that became exercisable in four annual installments of 16,000 shares each beginning on February 14, 2011 and as to the remaining 14,125 shares on February 14, 2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 08, 2017 Filed Feb 9, 2017 22:21 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
SaleCommon Stock | 4,756 | $142.19 | $676,277.04 |
DisclosureSEC source: 0001140361-17-005455 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 990,486 F2 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: Represents the weighted average sales price of the shares sold ranging from a low of $142.03 to a high of $142.83 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 08, 2017 Filed Feb 9, 2017 22:21 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
SaleCommon Stock | 31,494 | $141.55 | $4,457,893.82 |
DisclosureSEC source: 0001140361-17-005455 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 995,242 F2 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sales price of the shares sold ranging from a low of $141.02 to a high of $142.02 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 08, 2017 Filed Feb 9, 2017 22:21 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 36,250 | $26.66 | $966,243.75 |
DisclosureSEC source: 0001140361-17-005455 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,026,736 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 55 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on December 31, 2016. Read SEC document |
| February 08, 2017 Filed Feb 9, 2017 22:20 UTC |
JUNIUS DANIEL MDirector
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 3,000 | Not disclosed Strike: $64.69 | Not disclosed |
DisclosureSEC source: 0001140361-17-005453 · doc1.xml · derivative · entry 3 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,964 Underlying: Common Stock · 3,000 shares Expires 2024-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 2,987 shares on May 7, 2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split").? The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 08, 2017 Filed Feb 9, 2017 22:20 UTC |
JUNIUS DANIEL MDirector
|
SaleCommon Stock | 3,000 | $141.75 | $425,263.50 |
DisclosureSEC source: 0001140361-17-005453 · doc1.xml · nonDerivative · entry 2 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,495 F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $141.7031 to a high of $141.7765 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 08, 2017 Filed Feb 9, 2017 22:20 UTC |
JUNIUS DANIEL MDirector
|
Exercise / conversionCommon Stock | 3,000 | $64.69 | $194,070.00 |
DisclosureSEC source: 0001140361-17-005453 · doc1.xml · nonDerivative · entry 1 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2017 Filed Jan 31, 2017 22:07 UTC |
Kingsley Lawrence DDirector
|
GrantCommon Stock | 135 | $120.50 | $16,267.50 |
DisclosureSEC source: 0001140361-17-003779 · doc1.xml · nonDerivative · entry 1 Kingsley Lawrence D · CIK 0001301427 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($16,250.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| January 30, 2017 Filed Jan 31, 2017 22:07 UTC |
JUNIUS DANIEL MDirector
|
GrantCommon Stock | 41 | $120.50 | $4,940.50 |
DisclosureSEC source: 0001140361-17-003777 · doc1.xml · nonDerivative · entry 1 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,495 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($5,000.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| January 30, 2017 Filed Jan 31, 2017 22:06 UTC |
CRAIG THOMASDirector
|
GrantCommon Stock | 145 | $120.50 | $17,472.50 |
DisclosureSEC source: 0001140361-17-003774 · doc1.xml · nonDerivative · entry 1 CRAIG THOMAS · CIK 0001184156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,428 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($17,500.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 23:00 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-000505 · doc1.xml · derivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,386 Underlying: Common Stock · 2,820 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: These restricted stock units are part of a grant made to the reporting person on January 1, 2014 that have vested. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. F4 · price: Not applicable. F3 · derivative.exercise_date: These restricted stock units are part of a grant made to the reporting person on January 1, 2014 that have vested. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. F3 · derivative.expiration_date: These restricted stock units are part of a grant made to the reporting person on January 1, 2014 that have vested. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 23:00 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Tax withholdingCommon Stock | 1,105 | $117.27 | $129,583.35 |
DisclosureSEC source: 0001140361-17-000505 · doc1.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,311 F2 · price: Closing price of Issuer's common stock on the NASDAQ market on December 30, 2016. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 23:00 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionCommon Stock | 2,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-000505 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 285 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2016, June 30, 2016, September 30, 2016 and December 30, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.